Korean J Urol.  2009 Mar;50(3):229-236.

Pathologic Characteristics and Prognosis of Pathologic T0 Prostate Cancer

• Lee SR
• Ham WS
• Kim WT
• Ju HJ
• Lee JS
• Choi YD

Abstract

PURPOSE: We evaluated the pathologic characteristics and prognosis of pathologic T0 (pT0) prostate cancer (PC).
MATERIALS AND METHODS
Of 1,196 consecutive men who underwent radical prostatectomy (RP) between January 1992 and November 2008, 34 patients (mean age, 68.8+/-7.9 years; range, 48-85) had pT0 PC. They were categorized into 4 groups according to neoadjuvant hormone therapy (NHT) and diagnostic methods. The initial PSA, 5 alpha-reductase inhibitor (5alphaRI), Gleason score of prostatic needle biopsy (PNB) or transurethral resection of the prostate (TURP), clinical stage, and presence of high-grade prostatic intraepithelial neoplasia were evaluated. Clinical and biochemical progression were also evaluated.
RESULTS
34 patients were categorized into 4 groups (Group I: 9 without NHT, diagnosed by PNB [1.1%]; Group II: 8 without NHT, diagnosed by TURP [11.3%]; Group III: 16 with NHT, diagnosed by PNB [5.5%]; Group IV: 1 with NHT, diagnosed by TURP [3.8%]). Group I had serum prostate-specific antigen (PSA)<15.0 ng/ml, one positive biopsy core, and a Gleason score< or =7. Group II had serum PSA<10.1 ng/ml, chips involved with cancer<10.0%, and a Gleason score< or =6. There were more patients taking 5alphaRI and high-grade PIN among patients without NHT. None of patients with pathologic pT0 PC had clinical or biochemical progression during follow-up, except 3 patients with NHT (mean, 22 months; range, 2-105 months).
CONCLUSIONS
Patients without NHT had more favorable clinical and pathologic results. In our study, except for 3 patients with NHT, all patients had undetectable PSA levels after RP. We need more time for follow-up to conclude whether the prognosis of pT0 PC is favorable.

Keyword

Prostatic neoplasms; Prostatectomy

MeSH Terms

Biopsy
Biopsy, Needle
Cholestenone 5 alpha-Reductase
Follow-Up Studies
Humans
Male
Neoplasm Grading
Prognosis
Prostate
Prostate-Specific Antigen
Prostatectomy
Prostatic Intraepithelial Neoplasia
Prostatic Neoplasms
Transurethral Resection of Prostate
Cholestenone 5 alpha-Reductase
Prostate-Specific Antigen

Reference

1.Elgamal AA., Cornillie FJ., Van Poppel HP., Van de Voorde WM., McCabe R., Baert LV. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. J Urol. 1996. 156:1042–7.

2.Dall'Era MA., Cooperberg MR., Chan JM., Davies BJ., Albertsen PC., Klotz LH, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008. 112:1650–9.

3.Bostwick DG., Montironi R. Evaluating radical prostatectomy specimens: therapeutic and prognostic importance. Virchows Arch. 1997. 430:1–16.

4.Goldstein NS., Bégin LR., Grody WW., Novak JM., Qian J., Bostwick DG. Minimal or no cancer in radical prostatectomy specimens. Report of 13 cases of the “vanishing cancer phenomenon”. Am J Surg Pathol. 1995. 19:1002–9.

5.DiGiuseppe JA., Sauvageot J., Epstein JI. Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol. 1997. 21:174–8.

6.Descazeaud A., Zerbib M., Flam T., Vieillefond A., Debré B., Peyromaure M. Can pT0 stage of prostate cancer be predicted before radical prostatectomy? Eur Urol. 2006. 50:1248–52.

7.van der Kwast TH., Têtu B., Candas B., Gomez JL., Cusan L., Labrie F. Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology. 1999. 53:523–9.

8.Prezioso D., Lotti T., Polito M., Montironi R. Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study. Urol Int. 2004. 72:189–95.

9.Köllermann J., Feek U., Müller H., Kaulfuss U., Oehler U., Helpap B, et al. Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma. Eur Urol. 2000. 38:714–20.

10.Herkommer K., Kuefer R., Gschwend JE., Hautmann RE., Volkmer BG. Pathological T0 prostate cancer without neo-adjuvant therapy: clinical presentation and follow-up. Eur Urol. 2004. 45:36–41.

11.Lee KC., Lee KR., Kim HJ., Kim DS., Yoon DK., Cho JH. A case of no residual cancer in radical prostatectomy specimens despite biopsy-proven prostate cancer. Korean J Urol. 2001. 42:447–9.

12.Greene F., Page D., Fleming I. AJCC cancer staging manual. 6th ed.New York: Springer-Verlag;2002.

13.Freedland SJ., Sutter ME., Dorey F., Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003. 61:365–9.

14.Bostwick DG., Bostwick KC. ‘Vanishing' prostate cancer in radical prostatectomy specimens: incidence and long-term follow-up in 38 cases. BJU Int. 2004. 94:57–8.

15.Buttyan R., Ghafar MA., Shabsigh A. The effects of androgen deprivation on the prostate gland: cell death mediated by vascular regression. Curr Opin Urol. 2000. 10:415–20.

16.Sutton MT., Yingling M., Vyas A., Atiemo H., Borkowski A., Jacobs SC, et al. Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells. Prostate. 2006. 66:1194–202.

17.McNeal JE. Origin and development of carcinoma in the prostate. Cancer. 1969. 23:24–34.

18.Cao D., Hafez M., Berg K., Murphy K., Epstein JI. Little or no residual prostate cancer at radical prostatectomy: vanishing cancer or switched specimen?: a microsatellite analysis of specimen identity. Am J Surg Pathol. 2005. 29:467–73.

19.Epstein JI., Walsh PC., Carmichael M., Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994. 271:368–74.